The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 233-240

  Shin, Eunju ^a   Lisci, Carlo ^b   Tronci, Elisabetta ^b   Fidalgo, Camino ^b   Stancampiano, Roberto ^b   Björklund, Anders ^a   Carta, Manolo ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Buspirone; Cell transplantation; Eticlopride; Graft induced dyskinesia; L DOPA induced dyskinesia; Parkinson's disease; SCH23390

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; ANTIPARKINSON AGENT; BUSPIRONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ROPINIROLE; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDYSKINETIC ACTIVITY; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DISEASE SEVERITY; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DYSKINESIA; ENZYME ACTIVATION; FEMALE; GRAFT INDUCED DYSKINESIA; GRAFT SURVIVAL; LOW DRUG DOSE; NONHUMAN; PARKINSONISM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT OUTCOME;

BUSPIRONE; CELL TRANSPLANTATION; DOPAMINE D(1) RECEPTOR; DOPAMINE D(2) RECEPTOR; ETICLOPRIDE; GRAFT-INDUCED DYSKINESIA; L-DOPA-INDUCED DYSKINESIA; PARKINSON'S DISEASE; SCH23390;

AMPHETAMINE; ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; BENZAZEPINES; BUSPIRONE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINERGIC NEURONS; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; LEVODOPA; MESENCEPHALON; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SEROTONIN RECEPTOR AGONISTS;

EID: 84886826502     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.021     Document Type: Article

References (39)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 1946, 94:239-247.
2. Barker R.A., Barrett J., Mason S.L., Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 2013, 12:84-91.
3. Bjorklund A. Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr. Opin. Neurobiol. 1992, 2:683-689.
4. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17:73-82.
5. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Bjorklund A., Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 2006, 21:657-668.
6. Carlsson T., Carta M., Winkler C., Bjorklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
7. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
8. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
9. Eison A.S., Temple D.L. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am. J. Med. 1986, 80:1-9.
10. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46months after transplantation for Parkinson's disease. N. Engl. J. Med. 1992, 327:1549-1555.
11. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
12. Garcia J., Carlsson T., Döbrössy M., Nikkhah G., Winkler C. Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation. Exp. Neurol. 2011, 232:270-279.
13. Grealish S., Jonsson M.E., Li M., Kirik D., Bjorklund A., Thompson L.H. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010, 133:482-495.
14. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5:627-628.
15. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 2001, 21:2889-2896.
16. Kleedorfer B., Lees A.J., Stern G.M. Buspirone in the treatment of levodopa induced dyskinesias. J. Neurol. Neurosurg. Psychiatry 1991, 54:376-377.
17. Lane E.L., Winkler C., Brundin P., Cenci M.A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 2006, 22:334-345.
18. Lane E.L., Soulet D., Vercammen L., Cenci M.A., Brundin P. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol. Dis. 2008, 32:220-228.
19. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol. Dis. 2009, 35:42-51.
20. Lane E.L., Vercammen L., Cenci M.A., Brundin P. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp. Neurol. 2009, 219:355-358.
21. Lee C.S., Cenci M.A., Schulzer M., Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123(Pt 7):1365-1379.
22. Li J.Y., Englund E., Widner H., Rehncrona S., Bjorklund A., Lindvall O., et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 2010, 25:1091-1096.
23. Lindvall O., Widner H., Rehncrona S., Brundin P., Odin P., Gustavii B., et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 1992, 31:155-165.
24. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 1994, 35:172-180.
25. McMillen B.A., Matthews R.T., Sanghera M.K., Shepard P.D., German D.C. Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J. Neurosci. 1983, 3:733-738.
26. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14years. Nat. Med. 2008, 14:507-509.
27. Nikkhah G., Olsson M., Eberhard J., Bentlage C., Cunningham M.G., Bjorklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 1994, 63:57-72.
28. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
29. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
30. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 2011, 26:1997-2003.
31. Redmond D.E., Vinuela A., Kordower J.H., Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol. Dis. 2008, 29:103-116.
32. Rijnders H.J., Slangen J.L. The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity. Psychopharmacology (Berl.) 1993, 111:55-61.
33. Scuvee-Moreau J., Giesbers I., Dresse A. Electrophysiological and microiontophoretic studies with buspirone: influence on the firing rate of central monoaminergic neurons and their responsiveness to dopamine, clonidine or GABA. Arch. Int. Physiol. Biochim. 1987, 95:439-446.
34. Shin E., Garcia J., Winkler C., Bjorklund A., Carta M. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol. Dis. 2012, 47:393-406.
35. Tronci E., Shin E., Bjorklund A., Carta M. Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neurosci. Res. 2012, 73:168-172.
36. Winkler C., Bentlage C., Nikkhah G., Samii M., Bjorklund A. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp. Neurol. 1999, 155:165-186.
37. Winkler C., Kirik D., Bjorklund A., Dunnett S.B. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog. Brain Res. 2000, 127:233-265.
38. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
39. Zetterstrom T., Herrera-Marschitz M., Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 1986, 376:1-7.